Skip to main content

Table 6 Every-4-week spiral CT tumor response rates in the 125 mg/m2 nab-paclitaxel cohort over 28 weeks

From: 18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer

Week

Patients (responders/evaluable), n/N

Response Rate, %

4

4/38

11

8

9/38

24

12

12/37

32

16

14/32

44

20

10/28

36

24

10/21

48

28

9/17

53

  1. CT computed tomography